Comparison baseline of four different radical hysterectomy approaches
We identified 517 patients who underwent radical hysterectomy for early-stage cervical cancer during inclusion period. Of these, 238 patients (40.03%) were selected for primary analyses (Figure 1). The majority of the patients had stage IB1 disease (89.92%). Tumour characteristics are summarized in Table 1. The ARH group included 32 patients with mean age of 50.13 ± 8.89 years old and mean BMI of 25.42 ± 3.24 kg/m2, of which 0 case (0.00%) for stage IA2, 31 cases (96.88%) for stage IB1, 1 case (3.13%) for stage IB2, 26 cases (81.25%) squamous cell carcinoma, 6 cases (18.75%) adenocarcinoma, 0 case (0.00%) adenosquamous carcinoma, and 16 cases (50.00%) received postoperative adjuvant therapy. Sixty-one patients were enrolled in the LRH group with 48.97 ± 8.59 years old of mean age, 24.06 ± 2.81 kg/m2 of mean BMI, of which 5 cases (8.20%) for stage IA2, 52 cases (85.25%) for stage IB1, 4 cases (6.56%) for stage IB2, 49 cases (80.33%) squamous cell carcinoma, 11 cases (18.03%) adenocarcinoma, 1 case (1.64%) adenosquamous carcinoma, and 33 cases (54.10%) received postoperative adjuvant therapy. The RRH group included 100 patients with 48.64 ± 9.89 years old of mean age, 24.12 ± 3.50 kg/m2 of mean BMI, of which 5 cases (5.00%) for stage IA2, 91 cases (91.00%) for stage IB1, 4 cases (4.00%) for stage IB2, 89 cases (89.00%) squamous cell carcinoma, 11 cases (11.00%) adenocarcinoma, 0 case (0.00%) adenosquamous carcinoma, and 55 cases (55.00%) received postoperative adjuvant therapy. The VRH group included 45 patients with 46.04 ± 8.16 years old of mean age, 24.15 ± 3.23 kg/m2 of mean BMI, of which 3 cases (6.67%) for stage IA2, 40 cases (88.89%) for stage IB1, 2 cases (4.44%) for stage IB2, 40 cases (88.89%) squamous cell carcinoma, 4 cases (8.89%) adenocarcinoma, 1 case (2.22%) adenosquamous carcinoma, and 22 cases (48.89%) received postoperative adjuvant therapy. Whereas there was no statistical significance of the mean age, BMI, FIGO stage, histology and postoperative adjuvant therapy in the four groups (P > 0.05).